Sorrento Therapeutics, Inc.

NASDAQ:SRNE

$0.0015 USD

$0.0 (-11.76%)

Volume
30.31K
Average Volume
205.49K
Market Capitalization
$826.92K
P/E Ratio
0.00
Dividend Yield
0.00%
Price Target
$
Year High
$0.25
Year Low
$0.00
Payout Ratio
$0.00
Current Ratio
$0.29

Industry, Sector & symbol

Stock Exchange NASDAQ Capital Market
CEO Dr. Henry H. Ji Ph.D.
Industry Biotechnology
Sector Healthcare
Current Symbol SRNE
CUSIP 83587F202
CIK 0000850261
Web https://www.sorrentotherapeutics.com
Phone 858 203 4100
Currency USD
Employees 949
Country US

Liquidity

Debt-to-Equity Ratio -1.90
Payout Ratio 0.00
Current Ratio 0.29
Quick Ratio 0.26
Cash Ratio 0.07

Sales & Book Value

Annual Sales $62.84M
Price / Sales 0.01
Cash Flow -0.73
Price / Cash Flow 0.00
Price / Book -0.03

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 3 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-1.37
Trailing P/E Ratio 0.00
PEG Ratio 0.00
P/E Growth 0.00
Net Income $-572.84M
Net Margin -911.60%
Pretax Margin -893.95%
Return on Equity -1904.94%
Return on Assets -121.15%

Financials Score

AltmanZ Score -10.88
Piotroski Score 3.00
Working Capital -131.84M
Total Assets 456.69M
Ebit -546.04M
Market Cap 826.92K
Total Liabilities 654.65M

Poll Results

About Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Stock

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft vers ... us host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills

2024-10-24 08:00:00

Bremen, Indiana--(Newsfile Corp. - October 24, 2024) - Digger Specialties Inc. (DSI), a leading manufacturer of outdoor living products, is pleased to announce the addition of a 3-5/8" mesh infill option for the Westbury® Sorrento Mesh Railing effective November 1, 2024. Designed to provide a sophisticated, contemporary style that enhances the visual appeal of decks, balconies and porches, Westbury Sorrento Mesh Railing features unmatched long term durability and resistance to the elements.

Sorrento Resources Announces Appointment of Alex Bugden as President and Chief Executive Officer

2024-09-03 09:00:00

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OTCQB: SRSLF) (the "Company") is pleased to announce that Mr.

Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter

2024-05-29 11:38:00

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that it has entered into a purchase agreement dated May 29, 2024 (the "Agreement") with Gold Hunter Resources Inc. (CSE: HUNT) ("Gold Hunter") for the sale of certain mineral claims around Gold Hunter's newly optioned MT property.

Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person

2024-05-08 09:00:00

Vancouver, British Columbia--(Newsfile Corp. - May 8, 2024) - SORRENTO RESOURCES LTD. (CSE: SRS) (OCTQB: SRSLF) (the "Company") is pleased to announce that Mr.

DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing

2024-05-01 10:00:00

Bremen, Indiana--(Newsfile Corp. - May 1, 2024) - Digger Specialties Inc. (DSI), a leading manufacturer of outdoor living products, is pleased to announce the introduction of Westbury® Sorrento Mesh Railing. Designed to provide a sophisticated, contemporary style that enhances the visual appeal of decks, balconies and porches, Westbury Sorrento Mesh Railing features unmatched long term durability and resistance to the elements.

Frequently Asked Questions

What is the current Sorrento Therapeutics, Inc. (SRNE) stock price?

Sorrento Therapeutics, Inc.(NASDAQ:SRNE) stock price is $0.0015 in the last trading session. During the trading session, SRNE stock reached the peak price of $4 while $1.0E was the lowest point it dropped to. The percentage change in SRNE stock occurred in the recent session was --11.76% while the dollar amount for the price change in SRNE stock was -$-0.0.

SRNE's industry and sector of operation?

The NASDAQ listed SRNE is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of SRNE?

Dr. Henry H. Ji Ph.D. | Chairman, President & Chief Executive Officer
Dr. Scott Schaus | Chief Technology Officer
|
|
|

How many employees does SRNE have?

Number of SRNE employees currently stands at 949. SRNE operates from 4955 Directors Place, San Diego, CA 92121, US.

Link for SRNE official website?

Official Website of SRNE is: https://www.sorrentotherapeutics.com

How do I contact SRNE?

SRNE could be contacted at phone #858 203 4100 and can also be accessed through its website. SRNE operates from 4955 Directors Place, San Diego, CA 92121, US.

How many shares of SRNE are traded daily?

The average number of SRNE shares traded daily for last 3 months was 205.49K.

What is the market cap of SRNE currently?

The market value of SRNE currently stands at $826.92K with its latest stock price at $0.0015